Medical Advances Get More Chances When Safety Issues Arise
This article was originally published in Pharmaceutical Approvals Monthly
Withdrawn “me too” NMEs were removed from the market sooner after post-marketing safety signals than first-in-class or advance-in-class NMEs, showing the importance of available alternative therapy (or the lack thereof) in post-marketing risk management decisions.
You may also be interested in...
US drugs with accelerated approval are more likely to experience a postmarket safety event, JAMA study finds; data sharing could be a solution to filling information gaps.
A Health Affairs study notes that the rate of serious post-marketing safety concerns has risen while PDUFA has pushed down drug review times, feeding into concerns about the increasing use of expedited approvals.
Efforts to foster innovation may have been the major theme for FDA in 2013, with new and expanded programs to expedite review of drugs for unmet medical needs dominating headlines, but senior agency officials also describe continued advances on the safety side of the regulatory equation.